Clinical analysis on the application value of human papillomavirus E6/E7 mRNA testing for screening under 30 years old
10.3760/cma.j.cn115455-20220630-00595
- VernacularTitle:人乳头瘤病毒E6/E7 mRNA检测在小于30岁宫颈癌筛查中的临床分析
- Author:
Ming ZHANG
1
;
Dongling JIN
;
Guanghui LI
;
Yaping WANG
Author Information
1. 大连市妇女儿童医疗中心（集团）妇产院区妇科门诊，大连 116033
- Keywords:
Uterine cervical neoplasms;
Young adult;
Screening;
Human papillomavirus E6/E7 mRNA
- From:
Chinese Journal of Postgraduates of Medicine
2022;45(11):1046-1049
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To evaluate the clinical value of human papillomavirus (HPV) E6/E7 mRNA testing in cervical cancer screening under 30 years old.Methods:The clinical data of 330 young women (less than 30 years old) with minor abnormalities of thinprep cytologic test (TCT) screening for in Dalian Women′s and Children′s Medical Center (Group) Chunliu Region from January 2020 to June 2021 were retrospectively analyzed. Among them, 165 patients underwent HPV DNA typing test (DNA group), and 165 patients underwent HPV E6/E7 mRNA typing test (mRNA group). The positive rate of cervical intraepithelial neoplasia (CIN) Ⅱ and above (CIN Ⅱ +) was compared between two groups, and the positive rates of CIN Ⅱ + in different high risk HPV types. Results:The positive rate of high risk HPV types in mRNA group was significantly lower than that in DNA group: 32.7% (54/165) vs. 47.9% (79/165), and there was statistical difference ( χ2 = 7.87, P<0.05). There was no statistical difference in the incidence of CIN Ⅱ + of patients with positive of high risk HPV types between DNA group and mRNA: 45.6% (36/79) and 59.3% (32/54), P>0.05. There was no statistical difference in the incidence of CIN Ⅱ + of patients with HPV 16, 18 or 45 positive between DNA group and mRNA group: 38.5% (10/26) and 6/10, P>0.05. The incidence of CIN Ⅱ + of patients without HPV 16, 18 or 45 positive in mRNA group was significantly higher than that in DNA group: 60.9% (28/46) vs. 41.3% (26/63), and there was statistical difference ( P<0.05). Conclusions:Without increasing the rate of missed diagnosis, HPV E6/E7 mRNA testing plays an important shunt role in women under 30 years old, and the predicted value of CIN Ⅱ + is higher for patients who are not infected with HPV16/18/45 with HPV E6/E7 mRNA testing.
